3500% Dividend: Largecap IT Stock HCLTech Jumps On Renewed $278 Million Deal With apoBank; BUY?

The shares of HCL Technologies (HCLTech) saw a significant rise on June 12, climbing approximately 3% following the announcement of a $278 million contract renewal with Germany's apoBank. This renewed deal, spanning 7.5 years, underscores HCLTech's ongoing strength in the financial services sector and marks a significant win for the IT giant.

The newly renewed contract will see HCLTech implementing an outcome-oriented managed services model to deliver fast and secure banking services to apoBank's customers. This approach highlights HCLTech's focus on leveraging advanced technology solutions to enhance banking efficiency and security.

This deal win has been met with optimism from brokerage firm Morgan Stanley, which maintains an 'overweight' rating on HCLTech with a price target of Rs 1,650 per share. According to Morgan Stanley, the renewed deal with apoBank is indicative of HCLTech's robust momentum in securing large contracts within the financial services vertical. The firm notes that such deals are crucial for HCLTech to meet its full-year revenue targets, providing a solid foundation for future growth.

In addition to the apoBank deal, HCLTech has also strengthened its partnership with Olympus, a global leader in medtech. This extended partnership aims to drive advanced and affordable healthcare solutions through engineering technologies.

HCLTech and Olympus share a decade-long collaboration in engineering and R&D, encompassing product engineering, software engineering, product sustenance, and regulatory services. To support this expanded partnership, HCLTech will establish a dedicated product innovation centre in Hyderabad. This centre will cater to Olympus' operations across the US, Europe, the Middle East, and Africa, further solidifying HCLTech's position as a key player in the healthcare technology space.

As of 11:40 am on June 12, HCLTech's shares were trading at Rs 1,445.30 per share on the National Stock Exchange (NSE), reflecting gains of over 1%. Over the past year, HCLTech's stock has delivered returns of nearly 28%, and over the past three years, the stock has appreciated by 47%.

HCLTech has also demonstrated a strong track record of rewarding its shareholders through dividends. For the fiscal year ending March 2024, the company declared an equity dividend of 3500.00%, amounting to Rs 70 per share. At the current share price of Rs 1,448.75, this results in an impressive dividend yield of 4.83%. HCLTech has consistently declared dividends over the past five years.

HCLTech has a history of shareholder-friendly actions. The last bonus issue was in 2019, with a 1:1 ratio, and the shares have been quoting ex-bonus since December 5, 2019. Additionally, the last share split was in 2000, when the face value of shares was split from Rs 4 to Rs 2, effective from November 27, 2000.

Founded by Shiv Nadar, HCLTech is a leading Indian multinational IT consulting company headquartered in Noida. The company was spun out in 1991 when HCL entered the software services business. Today, HCLTech operates in 60 countries and employs over 225,000 people, making it a significant player in the global IT industry.

The renewal of the apoBank deal and the extended partnership with Olympus reflect HCLTech's strategic focus on expanding its footprint in both the financial services and healthcare sectors. These large, multi-year deals not only enhance HCLTech's revenue visibility but also reinforce its reputation for delivering innovative and reliable technology solutions.

With a robust pipeline of large deals and a strong financial position, HCLTech is well-positioned to continue its growth trajectory. Investors and analysts alike will be closely watching HCLTech's performance as it executes on these significant contracts and explores new opportunities for growth in an increasingly digital and technology-driven world.